CommercialCoverageMedium impact
Policy Criteria Changes
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Medical Policy
Effective date
Dec 15, 2025
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for Tislelizumab-jsgr (Tevimbra) to include FDA-labeled gastric cancer indication and revised off-label uses. Belantamab mafodotin-blmf (Blenrep) policy will be archived as HCPCS code J9037 becomes inactive March 31, 2025.
Action Required
By March 31, 2025: Billing team must stop using HCPCS code J9037 for Belantamab mafodotin-blmf (Blenrep) as it becomes inactive. Update billing software to remove this code and ensure proper prior authorization for Tislelizumab-jsgr when used for gastric cancer treatment per new FDA-labeled criteria.